Overview

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Status:
Completed

Trial end date:
2021-03-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Erenumab